摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-chloro-4-methyl-6-(1-piperazinyl)pyridazine | 100241-09-6

中文名称
——
中文别名
——
英文名称
3-chloro-4-methyl-6-(1-piperazinyl)pyridazine
英文别名
3-chloro-4-methyl-6-piperazin-1-ylpyridazine
3-chloro-4-methyl-6-(1-piperazinyl)pyridazine化学式
CAS
100241-09-6
化学式
C9H13ClN4
mdl
——
分子量
212.682
InChiKey
IQIRDYLRYALBIS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    440.7±45.0 °C(Predicted)
  • 密度:
    1.233±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    41
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:d6f030e8e06b5c7db79546b65634ec89
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-chloro-4-methyl-6-(1-piperazinyl)pyridazine 在 palladium on activated charcoal 氢气 作用下, 以 甲醇 为溶剂, 反应 3.0h, 生成 5-Methyl-3-(piperazin-1-yl)pyridazine
    参考文献:
    名称:
    Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists
    摘要:
    A structurally biased chemical library of pyridazinylpiperazine analogs was prepared in an effort to improve the pharmaceutical and pharmacological profile of the lead compound N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC). The library was evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH 5.5-induced (pH) FLIPR assays in a human VR1-expressing HEK293 cell line. The most potent VR1 antagonists were found to have IC50 values in the range of 9-200nM with improved pharmaceutical and pharmacological profiles versus the lead BCTC. These compounds represent possible second-generation BCTC analogs. (C) 2004 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2004.09.010
  • 作为产物:
    描述:
    ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate异丙醚正丁醇氢氧化钾 作用下, 以 为溶剂, 以17 parts (100%)的产率得到3-chloro-4-methyl-6-(1-piperazinyl)pyridazine
    参考文献:
    名称:
    Anti-virally active pyridazinamines
    摘要:
    抗病毒活性吡啶并胺,含有该物质的组合物以及治疗温血动物病毒性疾病的方法。
    公开号:
    US05001125A1
  • 作为试剂:
    描述:
    ethyl 4-(6-chloro-5-methyl-3-pyridazinyl)-1-piperazinecarboxylate氢氧化钾氯仿异丙醚3-chloro-4-methyl-6-(1-piperazinyl)pyridazine 作用下, 以 正丁醇 为溶剂, 反应 16.0h, 以yielding 17 parts (100%) of 3-chloro-4-methyl-6-(1-piperazinyl)pyridazine (compound 224)的产率得到
    参考文献:
    名称:
    Anti-virally active pyridazinamines
    摘要:
    抗病毒活性的吡啶嗪胺、含有该物质的组合物以及治疗温血动物病毒性疾病的方法。
    公开号:
    US05001125A1
点击查看最新优质反应信息

文献信息

  • Novel (4-substituted-piperazinyl)pyridazines
    申请人:——
    公开号:EP0211457A3
    公开(公告)日:1987-07-22
    Novel (4-substituted-piperazinyl)pyridazines of formula wherein R is hydrogen, halo, C1-6alkyloxy, hydroxy or phenyl; m is the integer 2 or 3; R¹, R², R³ and R⁴ are, each independently, hydrogen, or C1-6alkyl; or where R³ and R⁴ are substituted on a different carbon atom, R³ and R⁴ taken together, may form a bivalent radical -CH₂-CH₂-; R⁵ is (aryl)C2-6alkenyl, (aryl)C2-6alkynyl, (aryl)(hydroxy)­C1-6alkyl or (aryl)(oxo)C1-6alkyl; the N-oxide forms, the pharmaceutically acceptable acid addition salts and the possible stereochemically isomeric forms, which compounds are analgesic and antitussive agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.
    新型(4-取代哌嗪基)吡啶嗪的化学式如下: 其中R为氢、卤素、C1-6烷氧基、羟基或苯基; m为整数2或3; R¹、R²、R³和R⁴分别独立地为氢或C1-6烷基; 或者当R³和R⁴在不同的碳原子上取代时,R³和R⁴一起可以形成二价基团-CH₂-CH₂-; R⁵为(芳基)C2-6烯基、(芳基)C2-6炔基、(芳基)(羟基)C1-6烷基或(芳基)(羰基)C1-6烷基; 这些化合物包括N-氧化物形式、药学上可接受的酸盐和可能的立体化异构体形式,这些化合物是镇痛和镇咳剂;含有这类化合物作为活性成分的药物组合物以及制备这些化合物和药物组合物的方法。
  • Therapeutic agents useful for treating pain
    申请人:Kyle Donald J.
    公开号:US20080200472A1
    公开(公告)日:2008-08-21
    A compound of formula: wherein X is S or O and A, R 1 , R 2 , R 3 , R 4 , n, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Pyridazinylpiperazine Compound”), compositions comprising a Pyridazinylpiperazine Compound, and methods for treating or preventing pain, UI, an ulcer, IBD and IBS in an animal comprising administering to an animal in need thereof an effective amount of a Pyridazinylpiperazine Compound are disclosed herein.
  • US5001125A
    申请人:——
    公开号:US5001125A
    公开(公告)日:1991-03-19
  • US5157035A
    申请人:——
    公开号:US5157035A
    公开(公告)日:1992-10-20
  • US5292738A
    申请人:——
    公开号:US5292738A
    公开(公告)日:1994-03-08
查看更多